3 unknown. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Unknown 3 |
| Phase 3 | 1 | Unknown 1 |
Follow Pertussis: new trials by email Literature Review of Pertussis trials Research Report on Pertussis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age LR20062, DTaP-HepB-IPV-Hib vaccine - Diphtheria, Tetanus | Phase 2 | Unknown | LG Chem | 336 | 2024-10-02 | 2024-10-01 |
| Safety and Immunogenicity of 2 Doses Versus 1 Dose of Acellular Pertussis Vaccines Containing Genetically-detoxified Pertussis Toxin in Young Adults Previously Primed With Acellular Pertussis Vaccines Pertagen®, Revaxis® - Pertussis, Vaccine-Preventable Diseases | Phase 2 / Phase 3 | Unknown | University Hospital, Geneva | 100 | 2022-02-07 | 2022-01-18 |
| Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants DTwP-HepB-Sabin IPV-Hib, Pentavalent vaccine and Salk IPV - Diphtheria, Tetanus | Phase 2 | Unknown | LG Chem | 336 | 2019-11-01 | 2019-09-06 |
Whooping Cough (3) · Diphtheria (2) · Haemophilus Infections (2) · Hepatitis B (2) · Poliomyelitis (2) · Tetanus (2) · Vaccine-Preventable Diseases (1)
Bacterial Infections (3) · Bacterial Infections and Mycoses (3) · Bordetella Infections (3) · Gram-Negative Bacterial Infections (3) · Infections (3) · Respiratory Tract Diseases (3) · Respiratory Tract Infections (3) · Actinomycetales Infections (2) · Blood-Borne Infections (2) · Central Nervous System Diseases (2) · Central Nervous System Infections (2) · Clostridium Infections (2) · Communicable Diseases (2) · Corynebacterium Infections (2) · DNA Virus Infections (2)
FHD (1) · Vaccines, Combined (1)
LG Chem (2) · University Hospital, Geneva (1)
Switzerland (1)